Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

$44.11

+1.80 (+4.25%)

(As of 04/17/2024 ET)

Ultragenyx Pharmaceutical Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$91.55
107.54% Upside

High Forecast	$133.00
Average Forecast	$91.55
Low Forecast	$48.00

Type	Current Forecast 4/19/23 to 4/18/24	1 Month Ago 3/20/23 to 3/19/24	3 Months Ago 1/19/23 to 1/19/24	1 Year Ago 4/19/22 to 4/19/23
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$91.55	$91.55	$89.50	$88.67
Predicted Upside	107.54% Upside	104.72% Upside	107.77% Upside	95.62% Upside

Get Ultragenyx Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

RARE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RARE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ultragenyx Pharmaceutical Stock vs. The Competition

Type	Ultragenyx Pharmaceutical	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	107.54% Upside	935.55% Upside	12.25% Upside
News Sentiment Rating	Neutral News	Neutral News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
4/16/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$48.00	+11.09%
4/5/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$107.00	+125.93%
3/18/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$88.00 ➝ $92.00	+92.71%
2/21/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$110.00 ➝ $111.00	+131.88%
1/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$57.00 ➝ $68.00	+51.68%
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$72.00	+73.83%
11/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$90.00 ➝ $84.00	+123.34%
10/25/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$135.00 ➝ $130.00	+298.77%
8/1/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00	+90.17%
6/7/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$130.00 ➝ $133.00	+158.35%
6/6/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$60.00 ➝ $80.00	+56.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:02 AM ET.

RARE Price Target - Frequently Asked Questions

What is Ultragenyx Pharmaceutical's consensus rating and price target?: According to the issued ratings of 10 analysts in the last year, the consensus rating for Ultragenyx Pharmaceutical stock is Moderate Buy based on the current 1 hold rating and 9 buy ratings for RARE. The average twelve-month price prediction for Ultragenyx Pharmaceutical is $91.55 with a high price target of $133.00 and a low price target of $48.00. Learn more on RARE's analyst rating history.
Do Wall Street analysts like Ultragenyx Pharmaceutical more than its competitors?: Analysts like Ultragenyx Pharmaceutical more than other Medical companies. The consensus rating score for Ultragenyx Pharmaceutical is 2.90 while the average consensus rating score for medical companies is 2.68. Learn more on how RARE compares to other companies.
Does Ultragenyx Pharmaceutical's stock price have much upside?: According to analysts, Ultragenyx Pharmaceutical's stock has a predicted upside of 107.72% based on their 12-month stock forecasts.

What analysts cover Ultragenyx Pharmaceutical?: Ultragenyx Pharmaceutical has been rated by Canaccord Genuity Group, Cantor Fitzgerald, JPMorgan Chase & Co., Robert W. Baird, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:RARE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

RARE Analyst Ratings By Month

RARE Price Targets by Month

Ultragenyx Pharmaceutical Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

RARE Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info